ravulizumab-cwvz subcutaneous injection — Medica

Initial criteria

• Patient age ≥ 18 years
• Patient does not have Shiga toxin E. coli-related hemolytic uremic syndrome
• Patient has received or will receive Ultomiris intravenous infusion loading dose prior to initiation of Ultomiris subcutaneous
• Medication is prescribed by or in consultation with a nephrologist

Approval duration

1 year